DRUGS是SCI吗

您当前的位置: 首页 > SCI投稿 > DRUGS是SCI吗

Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy

Abstract:

While screening programs and HPV vaccination have decreased the incidence of cervical cancer, still over 13,000 cases occur in the USA annually. Early-stage cervical cancer has an excellent long-term prognosis, with 5-year survival for localized disease being > 90%. Survival decreases markedly for both locally advanced and metastatic disease, and both are associated with a higher risk of recurrence. Few effective treatment options exist for persistent, recurrent, or metastatic cervical cancer. In 2014, the anti-VEGF antibody bevacizumab was approved in combination with chemotherapy based on the results of the Phase III GOG-240 study. As the majority of cervical cancers have a viral etiology, which impairs the immune system, immunotherapy using checkpoint inhibitors and other agents, appears to be a promising approach. In June 2018, the US FDA approved the anti-PD1 antibody pembrolizumab for recurrent or metastatic cervical cancer with PD-L1 expression that progressed after one or more lines of chemotherapy. Another anti-PD1 antibody, cemiplimab also shows potential in this setting, either as monotherapy or combined with radiotherapy, and it is currently being evaluated in a Phase III trial. Additional checkpoint inhibitors including nivolumab, durvalumab, atezolizumab, and camrelizumab are in different stages of clinical development for the disease. Finally, an additional targeted approach being pursued involves PARP inhibitors (rucaparib and olaparib are both in Phase II) based on earlier study results.

展开更多

DRUGS

最新影响因子：11.431	期刊ISSN：0012-6667	CiteScore：4.72
出版周期：Monthly	是否OA：YES	出版年份：1971

期刊官方网址：http://link.springer.com/journal/40265

期刊投稿地址：http://www.springer.com/journal/40265/submission

自引率：1.20%	研究方向：医学-毒理学
出版地区：NEW ZEALAND

SCI期刊coverage：Science Citation Index Expanded（科学引文索引扩展）

NCBI查询：PubMed Central (PMC)链接全文检索(pubmed central)

专业编辑在线一对一答疑及时解决您的问题

DRUGS 期刊简介

英文简介：

Drugs is the definitive journal of drugs and therapeutics. It provides essential information required by all healthcare practitioners, teachers and researchers through independent and objective evaluations of drugs and their place in patient management. A comprehensive program of single agent drug reviews, drug class reviews and comparative reviews makes Drugs an essential Library title and an invaluable teaching tool. Drugs provides you with all the important and most current information on drug use to achieve optimal patient outcomes.

中文简介：（来自Google、百度翻译）

《药物》是药物和治疗学的权威杂志。它通过对药物及其在患者管理中的地位进行独立客观的评估，提供所有医疗从业者、教师和研究人员所需的基本信息。一个由单剂药物评论、药物课程评论和比较评论组成的综合性课程，使药物成为一个重要的图书馆标题和一个宝贵的教学工具。药物为您提供所有关于药物使用的最重要和最新信息，以实现最佳患者结果。

申请加急绿色通道，投稿周期比同行快2-3个月现在咨询

DRUGS 期刊中科院评价数据

影响因子趋势图

无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询

DRUGS 期刊CiteScore评价数据

CiteScore排名

序号	类别	排名	百分位
1	大类(学科)：Medicine 小类(学科)：Pharmacology (medical)	#7/230 点击查看排名表	97th

CiteScore趋势图

Scopus涵盖范围

无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询

DRUGS 期刊常见问题

权益保障

刊物信息可查

推荐刊物均可到国家新闻出
版总署网站查询正刊
严格保密协协议

可签署保密协议，不透露任
何用户信息可跟踪进程，全程
协议
售后服务保障

1对1服务，7x24小时在线
企业信誉保障

15年经验沉淀，实体公司
运营

DRUGS 投稿经验

(由下方点评分析获得，0人参与，10078人阅读）

偏重的研究方向：

暂无
投稿录用比例：

暂无
审稿速度：

暂无

年度总发文量	年度论文发表量	年度综述发表量
162	74	88

Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy